Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling

Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with diabetes. The mechanism underlying the beneficial effect of SGLT2 inhibitors i...

Full description

Bibliographic Details
Main Authors:	William Durante, Ghazaleh Behnammanesh, Kelly J. Peyton
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	International Journal of Molecular Sciences
Subjects:	sodium-glucose co-transporter 2 inhibitors diabetes endothelial dysfunction cardiovascular disease neointima formation arterial stiffness
Online Access:	https://www.mdpi.com/1422-0067/22/16/8786

Similar Items

C-fos, response to injury and local drug delivery in vascular models
by: Armstrong, Johanna
Published: (1999)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

Sodium-glucose co-transporter 2 inhibitors – a review article
by: Marcin Makuch, et al.
Published: (2019-08-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01)

Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice
by: Tzu-Hsien Tsai, et al.
Published: (2019-06-01)

Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study
by: Junichi Okada, MD, PhD, et al.
Published: (2020-01-01)

Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
by: Viraj Ramesh Suvarna
Published: (2021-01-01)

Functions of TRF2: From Telomere Protection to DNA Damage Signaling and Vascular Remodeling
by: Khan, Sheik Jamaludin
Published: (2008)

Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool
by: Sanjay Kalra, et al.
Published: (2017-01-01)

Cardiovascular effects of sodium glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus
by: Surender Kumar, et al.
Published: (2019-01-01)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
by: Resham Raj Poudel
Published: (2013-01-01)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
by: Koki Chiba, et al.
Published: (2021-02-01)

Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells
by: Kurosu Katsushi, et al.
Published: (2011-08-01)

Neointimal formation in two apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility
by: Weibin Shi, et al.
Published: (2004-11-01)

Calcium Phosphate Bions Cause Intimal Hyperplasia in Intact Aortas of Normolipidemic Rats through Endothelial Injury
by: Daria Shishkova, et al.
Published: (2019-11-01)

DISRUPTIONS OF ELASTIC ARTERIES PROPERTIES AND ENDOTHELIAL FUNCTION: MODERN METHODS FOR CORRECTION AND PREVENTION
by: A. F. Kolpakova
Published: (2015-06-01)

Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials
by: Bingshu Wu, et al.
Published: (2019-03-01)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
by: Kamlesh Khunti, et al.
Published: (2021-07-01)

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report
by: Miho Nakamura, et al.
Published: (2020-01-01)

Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
by: Stephen Melnick, et al.
Published: (2018-09-01)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020-09-01)

Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
by: Caiyun Zheng, et al.
Published: (2021-04-01)

Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study
by: Bin Zhao, et al.
Published: (2021-08-01)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following <i>In Vitro</i> Vascular Ischemia/Reperfusion Injury in Rats
by: Sevil Korkmaz-Icöz, et al.
Published: (2021-07-01)

Impact of mood on endothelial function and arterial stiffness in bipolar disorder
by: Samantha L Schmitz, et al.
Published: (2018-01-01)

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
by: Atsushi Tanaka, et al.
Published: (2020-12-01)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
by: Hidekatsu Yanai, et al.
Published: (2021-04-01)

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin
by: M. M. Batyushin
Published: (2021-04-01)

Cardiovascular Risk Factors and Their Relationship with Vascular Dysfunction in South African Children of African Ancestry
by: Edna N. Matjuda, et al.
Published: (2021-01-01)

Effectiveness of HIIT compared to moderate continuous training in improving vascular parameters in inactive adults
by: Robinson Ramírez-Vélez, et al.
Published: (2019-02-01)

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
by: Megumi Yasuda, et al.
Published: (2020-05-01)

Vascular Remodeling Markers in Patients with Essential Arterial Hypertension Depending on Presence of Type 2 Diabetes Mellitus
by: Yu. A. Danilogorskaya, et al.
Published: (2019-07-01)

Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor
by: Bhattarai, A.M, et al.
Published: (2022)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
by: Awadhesh Kumar Singh
Published: (2015-01-01)

Vascular ageing: main symptoms and mechanisms
by: I. D. Strazhesko, et al.
Published: (2012-08-01)

Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study
by: Tien-Hsing Chen, et al.
Published: (2020-11-01)

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
by: Keiichi Torimoto, et al.
Published: (2017-08-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Failure to confirm a sodium–glucose cotransporter 2 inhibitor‐induced hematopoietic effect in non‐diabetic rats with renal anemia
by: Daisuke Yamazaki, et al.
Published: (2020-07-01)

Cannot write session to /tmp/vufind_sessions/sess_7kdpck6kf61auseijqru9v6me9